行情

CCXI

CCXI

ChemoCentryx
NASDAQ

实时行情|Nasdaq Last Sale

18.20
+0.23
+1.28%
盘后: 18.03 -0.17 -0.93% 19:43 09/24 EDT
开盘
18.03
昨收
17.97
最高
18.41
最低
17.72
成交量
213.76万
成交额
--
52周最高
70.29
52周最低
9.53
市值
12.72亿
市盈率(TTM)
-10.2871
分时
5日
1月
3月
1年
5年
22 只股票在周五的盘前交易时段内波动
Gainers Focus Universal Inc. (NASDAQ: FCUV) rose 42% to $15.24 in pre-market trading. The company’s shares jumped around 65% over the previous month.
Benzinga · 2天前
这就是为什么 ChemoCentryx (CCXI) 被列入 Wasatch Small Cap 的批评者名单
Wasatch Global Investors, an investment management firm, published its “Wasatch Small Cap Growth Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 6.32% was recorded by the fund’s investor class for the Q2 of 2...
Insider Monkey · 5天前
您是否应该“出售”ChemoCentryx (CCXI) 股票?
Wasatch Micro Cap Fund recently released its Q2 2021 Investor Letter, a copy of which you can download here. The fund posted a return of 3.11% for the quarter, underperforming its benchmark, the Russell Microcap Index which returned 4.14% in the same quart...
Insider Monkey · 6天前
期权市场是否会预测 ChemoCentryx (CCXI) 股票的飙升?
Zacks.com · 09/15 13:47
ChemoCentryx 的资本使用回报率概览
Benzinga Pro data, ChemoCentryx (NASDAQ:CCXI) reported Q2 sales of $1.81 million. Earnings fell to a loss of $38.74 million, resulting in a 32.09% decrease from last quarter.
Benzinga · 09/13 16:57
下周的催化剂:Apple、Zoom Video、Palo Alto Networks 成为焦点;欧佩克更新
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 09/10 19:00
ChemoCentryx (CCXI) 自上次财报以来上涨 10.5%:还能继续吗?
Zacks.com · 09/08 09:15
ChemoCentryx 将参加两个即将举行的投资者会议
SAN CARLOS, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences: 2021 Virtual Wells Fargo ...
GlobeNewswire · 09/02 12:30
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CCXI最新的财务预测,通过CCXI每股收益,每股净资产,每股现金流等数据分析ChemoCentryx近期的经营情况,然后做出明智的投资选择。
分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CCXI价格均价为32.50,最高价位64.00,最低价为14.00。
EPS
机构持股
总机构数: 211
机构持股: 4,651.64万
持股比例: 66.54%
总股本: 6,990.35万
类型机构数股数
增持
55
664.72万
建仓
33
377.33万
减持
38
315.00万
平仓
69
1,786.59万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.45%
制药与医学研究
-1.02%
高管信息
Chairman/Chief Executive Officer/President/Director
Thomas Schall
Chief Financial Officer/Executive Vice President/Chief Administrative Officer/Secretary/Director/IR Contact Officer
Susan Kanaya
Chief Operating Officer/Executive Vice President
Tausif Butt
Treasurer
Markus Cappel
Lead Director/Independent Director
Thomas Edwards
Independent Director
Joseph Feczko
Independent Director
Rita Jain
Independent Director
Henry McKinnell
Independent Director
Geoffrey Parker
Independent Director
James Tyree
暂无数据
CCXI 简况
ChemoCentryx, Inc.(简称ChemoCentryx)是一家生物制药公司。该公司致力于发现、开发和商业化治疗孤儿与罕见疾病、自身免疫性疾病、炎症性疾病和癌症的口服疗法。该公司针对趋化系统,即包括趋化因子配体及其相关受体的分子网络,以及相关趋化受体从事业务。该公司的候选药物是多种靶向特定趋化因子或趋化受体的小分子,从而阻断由该特定受体驱动的负相关性炎症或抑制性应答,同时保持免疫系统其他部分的完整。该公司的产品包括针对孤儿与罕见疾病、免疫肿瘤学、慢性肾脏疾病和其他炎症与自身免疫性疾病的多个项目。

微牛提供ChemoCentryx Inc(NASDAQ-CCXI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CCXI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CCXI股票基本功能。